Here’s what happened to the CSL share price in June

CSL shares were relatively positive performers in June…

| More on:
A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • CSL's shares outperformed the ASX 200 index last month
  • This may have been driven by a broker note out of Citi
  • Its analysts are bullish and believe that plasma collections are now back to pre-COVID levels

The CSL Limited (ASX: CSL) share price had an eventful month in June.

Although the biotherapeutics giant’s shares ended the period largely flat, this was actually a very good outcome for investors.

That’s because the CSL share price was down by 6% in the middle of the month but rebounded strongly.

Furthermore, it was significantly better than the performance of the ASX 200 index, which lost approximately 9% of its value during the period.

Why did the CSL share price outperform?

The outperformance of the CSL share price appears to have been driven by the release of some bullish broker notes.

One of those came from the team at Citi, which retained its buy rating with a slightly trimmed price target of $330.00. This price target implies potential upside of almost 20% for investors over the next 12 months.

Citi highlighted that plasma collection levels have now returned to pre-COVID levels and immunoglobulins pricing is increasing. And with demand remaining strong for plasma products, the broker appears to believe the tide is now turning for CSL.

In light of this, the broker suspects that the market will start to focus on demand rather than supply. And given that demand is strong, it feels that this should bode well for the CSL share price performance in the coming months.

Citi explained:

Recently, there have been several data points influencing our view on the plasma sector. In this report, we review them and the implications for the sector as a whole. US CMS data indicates continued price increases in immunoglobulin products. This is consistent with our expectation, as donor fees continue to remain elevated.

Underlying demand for plasma products remains strong but supply is constrained due to low plasma collection volume. With plasma collections now back to pre-pandemic levels, we expect the market to shift its focus to the strong underlying plasma product demand. This should lead to strength in the CSL share price. Maintain Buy, A$330 TP.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man in his office leans back in his chair with his hands behind his head looking out his window at the city, sitting back and relaxed, confident in his ASX share investments for the long term.
Broker Notes

Why this broker sees plenty of upside for the ResMed share price

ResMed shares could be in the buy zone...

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

Looking to buy CSL shares? Here’s what to watch when the biotech company reports this week

Here’s what might be around the corner for CSL this earnings season.

Read more »

A scientist examining test results.
Healthcare Shares

Why did the Opthea share price dive 9% on Monday?

The biopharmaceutical company has announced new share issue arrangements.

Read more »

A disappointed female investor sits in front of her laptop and puts her hand to her forehead and closes her eyes in disappointment over share price falls
Capital Raising

Paradigm Biopharmaceuticals share price freefalls 27% following $66m cap raise

Paradigm shares have erased all of last week's gains...

Read more »

A woman stands facing a set of shelves that is completely empty.
Healthcare Shares

The ASX 200 company selling everything it makes due to its major competitor being out of the market: fundie

ResMed is performing strongly right now.

Read more »

a young woman props her hand under the face as she pokes her head out from under a luxurious doona in a bedroom decorated with flowers and a stylish lamp.
Healthcare Shares

Resmed share price dips despite profit and dividend boost

Profits and dividends are up, so why is the Resmed share price down?

Read more »

A sad looking scientist sitting and upset about a share price fall.
Earnings Results

Avita share price dives 16% on net loss

The medical technology company's shares are falling following today's financial results

Read more »

A man waking up happy with a smile on his face and arms outstretched representing the hefty Adairs dividend yield
Earnings Results

ResMed share price on watch following solid FY22 growth

ResMed has released its full year results...

Read more »